ClinicalTrials.gg
CompletedNCT01296412Updated Jun 9, 2017Results posted

Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)

A Phase 3 interventional study of sitagliptin and liraglutide in Diabetes Mellitus, Type 2, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2017-06-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
653
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
20th of 197
653 · median 102
Started
2011
with 12 others
Phase 3
74 of 198
none open now
Registered
97th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 20th largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2011, is one of 74 in phase 3, and was the 97th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study is being done to compare the effectiveness and safety of two treatment paradigms (oral sitagliptin with or without glimepiride versus liraglutide with or without increased dosing) for the treatment of participants with Type 2 Diabetes that is not adequately controlled with metformin alone. The primary hypothesis postulated that the mean change from baseline in hemoglobin A1c (A1C) in participants treated with a sitagliptin-based treatment is non-inferior to that of participants treated with a liraglutide-based

treatment.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus.
  • On stable dose of metformin monotherapy at a dose of at least 1500 mg per day for at least 12 weeks and a ≥7.0% and ≤11.0%.
  • Capable of using a liraglutide pen device.

Exclusion criteria

Exclusion criteria

  • History of Type 1 Diabetes mellitus.
  • Use of any oral antihyperglycemic agent (AHA) besides metformin, within the prior 12 weeks of screening.
  • Cardiovascular disorders within the past 3 months including acute coronary syndrome or new or worsening symptoms of coronary heart disease, coronary artery intervention, stroke, or transient ischemic neurological disorder.
  • Impaired liver function.
  • Impaired kidney function.
  • History of or hematological disorder that requires disease-specific treatment (chemotherapy, radiation therapy, surgery) or, in the opinion of the investigator, is likely to recur during the duration of the study.
  • History of leukemia, lymphoma, aplastic anemia, myeloproliferative or myelodysplastic diseases, thrombocytopenia, or malignant melanoma, regardless of the time since treatment.
  • Pregnancy or breastfeeding, or intention to become pregnant or donate eggs within the projected duration of the study.
  • Participation in another study with an drug or device within 12 weeks prior to screening.
  • History of or any to sitagliptin, liraglutide, glimepiride, or metformin based upon the labels of the country of the investigational site.
  • Participation in a weight loss program and not yet in maintenance phase, or starting of a weight loss medication (such as orlistat or phentermine) within the prior 8 weeks.
  • Surgery within the prior 4 weeks or major surgery planned during the study.
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
  • User of recreational or illicit drugs or recent history (within the last year) of drug abuse or increased alcohol consumption.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
653 participants (actual)

Study arms

  • Experimental
    Sitagliptin +/- glimepiride

    Sitagliptin 100 mg tablet orally once daily for 26 weeks. Participants continued their stable dose of metformin \>=1500 mg orally daily. Participants may have received glimepiride orally for glycemic control.

    Drug: sitagliptin · Drug: glimepiride · Drug: metformin

  • Active comparator
    Liraglutide

    Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin \>=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.

    Drug: liraglutide · Drug: metformin

Interventions

  • 100 mg tablet, orally, once daily.

    Also known as: MK-0431, Januvia®, Tesavel®, Xelevia®, Ristaben®

  • 0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.

    Also known as: Victoza®

  • starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.

    Also known as: Amaryl®

  • metformin tablets at a dose of ≥1500 mg per day

    Also known as: Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (A1C)

    A1C is measured as percent. Thus, this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent.

    Time frame: Baseline and Week 26

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG)

    Change from baseline at Week 26 is defined as Week 26 minus Week 0.

    Time frame: Baseline and Week 26

  2. Percentage of Participants Reaching A1C Goal of <7.0%

    Time frame: Week 26

  3. Percentage of Participants Reaching A1C Goal of <6.5%

    Time frame: Week 26

07

Results

Posted Mar 15, 2013

Participant flow

Participant flow — Overall Study
MilestoneSitagliptin +/- GlimepirideLiraglutide
Started326327
Completed275257
Not completed5170
Withdrew: Adverse event829
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up107
Withdrew: Non-compliance with study drug12
Withdrew: Other reason not specified2015
Withdrew: Physician decision13
Withdrew: Pregnancy01
Withdrew: Withdrawal by subject1013

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (A1C)

A1C is measured as percent. Thus, this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · percent
Change From Baseline in Hemoglobin A1c (A1C)
percentSitagliptin +/- GlimepirideLiraglutide
Change From Baseline in Hemoglobin A1c (A1C)-1.32 ± 1.06-1.42 ± 1.04
Statistical analysis
  • Sitagliptin +/- Glimepiride vs Liraglutide · ANCOVA · Difference in least squares mean: 0.09 · 95% CI -0.05 to 0.23The ANCOVA model included a term for treatment paradigm and a covariate for baseline value.
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Change from baseline at Week 26 is defined as Week 26 minus Week 0.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG)
mg/dLSitagliptin +/- GlimepirideLiraglutide
Change From Baseline in Fasting Plasma Glucose (FPG)-33.7 ± 46.2-39.6 ± 40.3
Statistical analysis
  • Sitagliptin +/- Glimepiride vs Liraglutide · ANCOVA · Difference in least squares mean: 5.9 · 95% CI 0.5 to 11.4The ANCOVA model included a term for treatment paradigm and a covariate for baseline value.
SecondaryPercentage of Participants Reaching A1C Goal of <7.0%
Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Reaching A1C Goal of <7.0%
percentage of participantsSitagliptin +/- GlimepirideLiraglutide
Percentage of Participants Reaching A1C Goal of <7.0%62.872.3
Statistical analysis
  • Sitagliptin +/- Glimepiride vs Liraglutide · Miettinen & Nurminen · Difference in percent: -9.5 · 95% CI -17.4 to -1.5
SecondaryPercentage of Participants Reaching A1C Goal of <6.5%
Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Reaching A1C Goal of <6.5%
percentage of participantsSitagliptin +/- GlimepirideLiraglutide
Percentage of Participants Reaching A1C Goal of <6.5%33.838.3
Statistical analysis
  • Sitagliptin +/- Glimepiride vs Liraglutide · Miettinen & Nurminen · Difference in percent: -4.5 · 95% CI -12.7 to 3.7

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin +/- Glimepiride—17/326 (5.2%)58/326 (17.8%)
Liraglutide—12/324 (3.7%)97/324 (29.9%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventSitagliptin +/- GlimepirideLiraglutide
Road traffic accidentInjury, poisoning and procedural complications2/3260/324
Non-cardiac chest painGeneral disorders1/3261/324
Prostatic specific antigen increasedInvestigations0/3261/324
OsteoarthritisMusculoskeletal and connective tissue disorders0/3261/324
Spinal column stenosisMusculoskeletal and connective tissue disorders0/3261/324
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3261/324
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3261/324
EncephalopathyNervous system disorders0/3261/324
SciaticaNervous system disorders0/3261/324
Transient ischaemic attackNervous system disorders0/3261/324
Most frequent other events
Most frequent other events
EventSitagliptin +/- GlimepirideLiraglutide
NauseaGastrointestinal disorders10/32663/324
HypoglycaemiaMetabolism and nutrition disorders41/32615/324
DiarrhoeaGastrointestinal disorders7/32635/324
VomitingGastrointestinal disorders6/32621/324
Decreased appetiteMetabolism and nutrition disorders4/32621/324

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sitagliptin +/- GlimepirideLiraglutideTotal
Mean56.9 ± 10.057.6 ± 10.857.3 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin +/- GlimepirideLiraglutideTotal
Female148147295
Male178180358
Hemoglobin A1c (A1C)
Hemoglobin A1c (A1C)(Percent)Sitagliptin +/- GlimepirideLiraglutideTotal
Mean8.2 ± 1.18.1 ± 0.98.2 ± 1.0
Fasting Plasma Glucose
Fasting Plasma Glucose(mg/dL)Sitagliptin +/- GlimepirideLiraglutideTotal
Mean174.1 ± 43.7172.9 ± 40.8173.5 ± 42.3
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, Prabhu V, Davies MJ, Engel SS. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Diabetologia. 2013 Jul;56(7):1503-11. doi: 10.1007/s00125-013-2905-1. Epub 2013 Apr 19. PubMed 23604551 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Feb 2012, 11 months.

Results were first posted in Mar 2013, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2011
First posted
Feb 15, 2011
StartActual
Mar 11, 2011
Primary completionActual
Feb 29, 2012
CompletionActual
Feb 29, 2012
Results first posted
Mar 15, 2013
Last update
Jun 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01296412
Responsible party
Sponsor
First posted
Feb 15, 2011
Start date
Mar 11, 2011
Primary completion
Feb 29, 2012
Completion
Feb 29, 2012
Results posted
Mar 15, 2013
Last update
Jun 9, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion